

FAST TRACK OSTEOPOROSIS ORDER FORM

| PATIENT INFORMATION | | | |
|--|-----------|---------------------------|---|
| Patient Name: | DOB: | Phone: | Demographics attached |
| INSURANCE INFORMATION: PLEASE ATTACH A COPY OF PRESCRIPTION/MEDICAL CARD(S), FRONT AND BACK | | | |
| MEDICAL INFORMATION | | | |
| Diagnosis: Osteoporosis Olucocorticoid-induced osteoporosis Paget's disease of bone | | | |
| Clinical/Progress Notes, Labs, Tests supporting primary diagnosis attached | | | |
| DEXA Scan, within 2 years (-2.5 T score or more severe) ** if no - 2.5 T score, documented FR RAAX ≥ 20% for major | | | |
| osteoporotic fracture or \geq 3% for hip fracture, documented fragility fracture, or any other notableble r risk factors | | | |
| Serum calcium WNL, within 30 days | | | |
| eGFR > 30 mL/min, within 30 days | | | |
| Serum 25-hydroxy vitamin D ≥ 30 ng//mL | | | |
| Tried & Failed Medications | | | |
| | Duration: | Reason for discontinuing: | |
| Fosamax/ alendronate | | | |
| Boniva/ ibandronate | | | |
| Actonel/ risedronate | | | |
| Reclast/ zoledronic acid | | | |
| Prolia/ denosumab | | | |
| Forteo/ teriparatide | | | |
| Tymlos/ abaloparatide | | | |
| Evenity/ romosozumabEvista/ raloxifene | | | |
| ZOLEDRONIC ACID | | | |
| | | | |
| * Patient is currently taking calcium/vitamin D supplementation O YES O NO Other Zoledronic Acid 5 mg IV once yearly dx: osteoporosis | | | |
| Zoledronic Acid 5 mg IV once yearly dx. osteoporosis Zoledronic Acid 5 mg IV every other year dx: osteopenia | | | |
| Zoledronic Acid 5 mg IV x1 dx: Paget's disease of the bone | | | |
| PROLIA | | | |
| * Patient is currently taking calcium/vitamin D supplementation YES NO Other | | | |
| Prolia 60 mg subcutaneous injection every 6 months | | | |
| EVENITY | | | |
| * Patient is currently taking calcium/vitamin D supplementation YES NO Other | | | |
| ** No history of MI or stroke within the past 12 months | | | |
| Evenity 210 mg subcutaneous injection once monthly (max 12 months) | | | |
| PROVIDER INFORMATION | | | |
| By signing this form and utilizing our services, you are authorizing Community Care Rheumatology and its staff to serve as your prior | | | |
| authorization and specialty pharmacy designated agent in dealing with medical and prescription insurance companies. | | | |
| Provider Signature: Date: | | | |
| Provider Name: | | | - |
| Phone: | Fax: | Contact Person: | |

IMPORTANT NOTICE: This fax is intended to be delivered only to the named addressee. It contains material that is confidential, privileged property or exempt from disclosure under applicable law. If you are not the named addressee, you should not disseminate, distribute or copy this fax. Please notify the sender immediately. If you have received this document in error and then destroy this document immediately.

